CUVL · Clinuvel Pharmaceuticals Ltd
Price & Indicators
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CUVL
this stock
Clinuvel Pharmaceuticals Ltd
|
$312.65M | -25.9% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$141.42B | +23.1% | +46.2% | 32.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.84B | +9.3% | +20.8% | 20.9 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.96B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CUVL | -7.2% | -3.4% | -23.3% | +5.6% | -25.9% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | -7.5% | -4.0% | -40.1% | +4.8% | -39.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.